Type of Document Dissertation Author Zeytun, Ahmet Author's Email Address firstname.lastname@example.org URN etd-052699-174350 Title Tumor cell-immune cell interaction: A lethal two way street Degree PhD Department Biology Advisory Committee
Advisor Name Title Nagarkatti, Prakash S. Committee Chair Eng, Ludeman A. Committee Member Esen, Asim Committee Member Nagarkatti, Mitzi Committee Member Turner, Bruce J. Committee Member Keywords
- Fas ligand
Date of Defense 1999-05-13 Availability unrestricted AbstractTUMOR CELLS-IMMUNE CELL INTERACTIONS: A LETHAL TWO WAY STREET By Ahmet Zeytun Dr. Prakash S. Nagarkatti, Chairman Biology (Abstract)
We investigated the role of Fas ligand in the development of anti-tumor immunity. The LSA tumor specific cytotoxic T lymphocyte (CTL) clone, PE-9, expressed both Fas and Fas ligand. This CTL clone upregulated Fas and Fas ligand expression upon activation through the T-cell receptor and induced apoptosis in Fas+, LSA tumor cells using the FasL-based pathway. However, LSA and EL-4 tumor cells constitutively expressed Fas ligand and killed Fas+ PE-9 CTLs and Fas+, but not Fas-negative (Fas-) activated T cells and thymocytes. These data suggested that T cells and cancer cells can kill each other and that cancer cells may use Fas ligand to evade the action of the immune T cells.
In addition to the expression of membrane-bound form, FasL+ LSA and EL-4 tumor cells produced a soluble form of Fas ligand when they grew in vivo and in vitro. Serum from EL-4 or LSA-bearing wild type mice contained significant levels of Fas ligand. The soluble FasL induced apoptosis in liver and thymus of C57BL/6 wild type (Fas+) mice, but not C57BL/6 lpr/lpr (Fas-) mice. The detection of apoptosis in the liver of C57BL/6 gld/gld (FasL-defective) mice suggested that the source of Fas ligand found in the sera of EL-4 or LSA-bearing mice was from the tumor cells rather than the host cells.
CTL or NK cells used FasL-based apoptosis to kill the target cells when activated. To this end, we tested whether constitutive expression of Fas on tumor cells generate enhanced anti-tumor immunity. IL-2 or poly-I-C induced/ activated NK/LAK cells displayed higher cytotoxicity against L1210 Fas+, but not L1210 Fas- tumor cells. Furthermore, growth of L1210 Fas+, but not Fas- tumor, in vivo, generated Fas-specific cytotoxic T lymphocytes. Therefore, mice bearing L1210 Fas+ tumor cells survived for a longer time than mice bearing L1210 Fas- tumor cells.
To determine the role of the Fas, FasL, and perforin in the initiation of tumor, C57BL/6 +/+ (FasL+, Fas+), C57BL/6 lpr/lpr (Fas-), C57BL/6 gld/gld (FasL-), and perforin knock-out (PKO) (FasL+, Fas+, but perforin-deficient) mice were injected with methylcholanthrane (MCA). Tumor development in lpr or gld mice was faster and uncontrollable, compared to C57BL/6 (wild-type) and PKO mice. However, wild-type and PKO mice showed delayed tumor appearence and were able to suppress tumor growth. In addition to the deficiency of Fas or FasL, high levels of TGF-b and IL-10 expression detected in lpr and gld mice were also responsible for the early tumor development.
Together these data suggested that interactions between Fas and Fas ligand, expressed on immune cells and tumor cells, play an important role in the generation of anti-tumor immunity. Tumor cells use FasL to evade the action of the immune system, and upregulation of FasL makes T cells more cytolytic. Tumor growth may depend on the number of cancer cells vs. the number of cancer specific T cells.
Filename Size Approximate Download Time (Hours:Minutes:Seconds)
28.8 Modem 56K Modem ISDN (64 Kb) ISDN (128 Kb) Higher-speed Access AZEYTUNDISS.PDF 1.77 Mb 00:08:12 00:04:13 00:03:41 00:01:50 00:00:09 FIGURE4.4.TIF 847.43 Kb 00:03:55 00:02:01 00:01:45 00:00:52 00:00:04 FIGURE4.5.TIF 851.71 Kb 00:03:56 00:02:01 00:01:46 00:00:53 00:00:04 FIGURE4.6.TIF 765.06 Kb 00:03:32 00:01:49 00:01:35 00:00:47 00:00:04 FIGURE4.7.TIF 765.06 Kb 00:03:32 00:01:49 00:01:35 00:00:47 00:00:04 FIGURE4.8.TIF 711.58 Kb 00:03:17 00:01:41 00:01:28 00:00:44 00:00:03
If you have questions or technical problems, please Contact DLA.